Denis A, Baudeau C, Verdy E, Couderc R, Rondeau E, Sraer J D
Laboratoire d'Hématologie, Hôpital Tenon, Paris, France.
Nouv Rev Fr Hematol (1978). 1995;37(2):165-9.
An acquired circulating anticoagulant with anti-factor V activity appeared in a 29 year old AIDS patient with widespread Kaposi's sarcoma following 21 days of fresh frozen plasma therapy for haemolytic and uraemic syndrome. Residual factor V activity was very low (< 5% of normal). However, the inhibitor was of low titre (0.5 Bethesda Units/ml), while antigenic factor V levels remained at 100%. Dot blotting with human factor V and polyvalent and specific immunoglobulin antisera showed the antibody to belong to the IgG class. Haemostatic tests in vitro were only partly corrected by addition of washed human platelets and despite transfusion of large amounts of platelets the patient died from massive pulmonary haemorrhage. This would appear to be the first documented case of an anti-factor V inhibitor occurring in an AIDS patient.
一名29岁患有广泛卡波西肉瘤的艾滋病患者，在接受21天新鲜冰冻血浆治疗溶血性尿毒症综合征后，出现了一种具有抗因子V活性的获得性循环抗凝物质。残余因子V活性非常低（<正常的5%）。然而，抑制剂滴度较低（0.5贝塞斯达单位/毫升），而抗原性因子V水平仍保持在100%。用人因子V以及多价和特异性免疫球蛋白抗血清进行斑点印迹显示，该抗体属于IgG类。体外止血试验仅通过添加洗涤后的人血小板得到部分纠正，尽管输注了大量血小板，患者仍死于大量肺出血。这似乎是首例记录在案的艾滋病患者出现抗因子V抑制剂的病例。
